Nuvalent (5AX) Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. More details

5AX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 76.8% below our estimate of its fair value

Revenue is forecast to grow 55.94% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

5AX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW495,827 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

495,827 investors already sharing narratives

View all narratives

Nuvalent, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nuvalent
Historical stock prices
Current Share Price	US$107.80
52 Week High	US$109.20
52 Week Low	US$77.20
Beta	1.14
1 Month Change	34.08%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	36.28%

Recent updates

Shareholder Returns

	5AX	DE Biotechs	DE Market
7D	-1.3%	1.5%	3.8%
1Y	n/a	16.6%	3.9%

Return vs Industry: Insufficient data to determine how 5AX performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 5AX performed against the German Market.

Price Volatility

Is 5AX's price volatile compared to industry and market?
5AX volatility
5AX Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.6%
10% most volatile stocks in DE Market	12.5%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 5AX's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 5AX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	234	Jim Porter	nuvalent.com

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies.

Nuvalent, Inc. Fundamentals Summary

How do Nuvalent's earnings and revenue compare to its market cap?
5AX fundamental statistics
Market cap	€8.55b
Earnings (TTM)	-€393.50m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-21.7x

P/E Ratio

Is 5AX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
5AX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$450.07m
Earnings	-US$450.07m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-5.70
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 5AX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/05 16:31
End of Day Share Price	2026/07/03 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvalent, Inc. is covered by 26 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Etzer Darout	Barclays
Jeffrey Walch	Bernstein

Nuvalent, Inc.DB:5AX Stock Report